Sarepta Therapeutics (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/31/20
Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/27/20
Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship ProgramGlobeNewsWire • 02/27/20
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
Sarepta Therapeutics, Inc. And Arrowhead Pharmaceuticals Now Top-Ranked Biotech Stock BuysSeeking Alpha • 02/01/20
Sarepta Therapeutics (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/31/20
Sarepta Snagged After FDA Sheds Light On Its Initial Drug RejectionInvestors Business Daily • 01/23/20
Are Options Traders Betting on a Big Move in Sarepta (SRPT) Stock?Zacks Investment Research • 01/20/20
Casimersen Is A Lead Catalyst For Sarepta Therapeutics As A Top 2020 Stock PickSeeking Alpha • 01/15/20
Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of DirectorsGlobeNewsWire • 01/13/20
Red-Hot Biotech Stocks Brace For Key Meeting — Here's What To ExpectInvestors Business Daily • 01/09/20
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 12/31/19
Sarepta: Roche Partnership After The FDA's Turnaround Forms The Basis For A $158.59 Near-Term Price TargetSeeking Alpha • 12/26/19